“Beyond PD-1/PD-L1: TME-Targeted Therapies in the Era of Immunotherapy Resistance”, J Biomol Pathog Ther, vol. 2, no. 1, pp. 1–3, Mar. 2026, doi: 10.68041/jbpt.v2i1/06.